PNPLA3 and metabolic dysfunction-associated steatotic liver disease: This study found that CpG26 in the regulatory region of PARVB variant 1 was significantly hypomethylation, and CpG99 of PNPLA3 were remarkably hypermethylation in the livers of patients with advanced MASLD relative to those with mild MASLD, respectively.